STOK
Stoke Therapeutics, Inc.
STOK
Stoke Therapeutics, Inc.
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations
Stoke Therapeutics remains a "Buy," driven by progress on zorevunersen for SCN1A Dravet Syndrome and robust clinical milestones ahead. The company expects an FDA meeting in H2 2026, rolling NDA submis
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics remains a speculative BUY, with a compelling disease-modifying approach for Dravet Syndrome and a robust RNA-based platform. Its Phase 3 EMPEROR trial for zorevunersen is now fully